New shot aims to prevent clots without bleeding risk
NCT ID NCT07655427
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a single injection of a new drug called SRSD107 in 48 healthy adults. The drug is designed to temporarily lower a clotting factor in the liver, potentially preventing dangerous blood clots with less bleeding risk than standard treatments. The main goal was to check safety and how the body processes the drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SRSD107 (a synthetic siRNA drug that targets a clotting factor to reduce blood clot risk)
What this could lead to
If successful, this could lead to a new injectable drug that lowers the risk of dangerous blood clots (like deep vein thrombosis or stroke) without increasing bleeding risk as much as current treatments.
What could go wrong
This is an early Phase 1 trial in only 48 healthy people, so safety and effectiveness are not yet proven. The drug may not work as expected or could cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tiantan Hospital Affiliated to Capital Medical University
Beijing, Beijing Municipality, China